Tatva Chintan Pharma Chem Ltd 2024 AR2
The report highlights Tatva Chintan Pharma Chem Limited's performance for the fiscal year 2023-24, showcasing resilience despite global chemical industry challenges. The company successfully commenced commercial production at its expanded Dahej SEZ facility, increasing total reactor capacity to 500 KL. Financially, consolidated revenue from operations stood at ’3,935.04 million, while EBITDA grew by 12.54% to ’682 million. On the sustainability front, the company advanced its green chemistry initiatives, with its Ankleshwar unit operating as a Zero Liquid Discharge facility and recycling 36% of its water.
Company: Tatva Chintan Pharma Chem Ltd
Sector: Materials
Country: India
Year: 2024
Type: AR2
Pages: 293
Tatva Chintan Pharma Chem Ltd
Annual Report
The report highlights Tatva Chintan Pharma Chem Limited's performance for the fiscal year 2023-24, showcasing resilience despite global chemical industry challenges. The company successfully commenced commercial production at its expanded Dahej SEZ facility, increasing total reactor capacity to 500 KL. Financially, consolidated revenue from operations stood at ’3,935.04 million, while EBITDA grew by 12.54% to ’682 million. On the sustainability front, the company advanced its green chemistry initiatives, with its Ankleshwar unit operating as a Zero Liquid Discharge facility and recycling 36% of its water.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees